Answers are grounded in this paper and cite their sources.
Pediatric obstructive sleep apnea (OSA) is characterized by upper airway obstruction, poor sleep, and daytime sequelae such as hyperactivity. Although controversy exists regarding the ideal evaluation for children with sleep-disordered breathing, the severity of OSA is currently determined by full-night polysomnogram (PSG). Mild OSA is defined by an apnea-hypopnea index (AHI) > 1 and <5. The majority (approximately 85%) of healthy school-aged children evaluated by otolaryngologists for tonsil hypertrophy and obstructive symptoms have either primary snoring or nonsevere OSA.1 The treatment of mild OSA in children is controversial. There is a lack of data on the natural history of mild sleep apnea. Furthermore, a poor correlation exists between quality of life (QOL) scores and OSA severity; mild OSA in children may have a significant impact on their general health and well-being. High-quality studies comparing observation, medical management, and surgery for mild pediatric OSA are just beginning to emerge. Many of these studies use varied measures to assess outcomes. Thus, it may be difficult for providers treating children with mild OSA to counsel parents on the optimal treatment for their child. Recent research has suggested that watchful waiting may be an effective therapeutic option for mild OSA. Much of the outcomes data regarding observation for pediatric OSA are derived from a multi-institutional randomized trial (Childhood Adenotonsillectomy Trial [CHAT]) comparing watchful waiting to early adenotonsillectomy for school-aged children with nonsevere OSA.1 In the CHAT cohort, almost 50% of children in the observation group had normalization of their AHI on PSG performed after 7 months of watchful waiting. Children who were obese, black, or those who had a higher baseline AHI (AHI > 4.7) were less likely to experience resolution of their obstruction. There was no difference in neurocognitive outcomes between the observation and adenotonsillectomy groups. Li et al.2 also reported on outcomes in children with mild OSA. After 2 years of observation, the AHI was either stable or had improved in 70% of subjects. Increase in waist circumference and significant tonsil hypertrophy were risk factors for disease progression. Despite improvements in some PSG parameters following a period of observation, symptomatology related to pediatric OSA may continue. In the observation arm of the CHAT cohort, only 25 of 194 children (15%) had improvement in symptoms related to their sleep-disordered breathing as assessed by the Pediatric Sleep Questionnaire (PSQ).1 Predictors of symptom resolution after 7 months included lack of habitual snoring, female gender, and low baseline PSQ score. It is important that clinicians counsel caregivers considering observation as a treatment option for mild OSA that symptoms such as snoring will likely persist. Long-term outcomes are lacking and future research is needed in this area. Based on our current review of the literature, children with mild OSA, who have significant tonsil hypertrophy, habitual snoring, and obesity, may not be ideal candidates for watchful waiting, as they are at risk for progression of their obstruction. Anti-inflammatory medications such as nasal steroid sprays and montelukast are another therapeutic option for the management of nonsevere pediatric OSA. A recent randomized, placebo-controlled trial3 examined the efficacy of 4 months of intranasal mometasone furoate treatment in children with mild OSA. There was a significant improvement in the AHI from 2.7 to 1.7 in children managed with nasal steroid spray, whereas there was no change in the AHI for those in the placebo group. Children with a history of allergic rhinitis were more likely to experience benefit from mometasone furoate. Montelukast, a leukotriene inhibitor, has also been shown to improve PSG parameters in children with mild OSA. In a recent double-blind, placebo-controlled trial,4 children in the montelukast group had significant improvement in the obstructive apnea index from 6.0 to 3.6 following 3 months of therapy. The children in the montelukast group also experienced a significant reduction in adenoid size as assessed by lateral neck film. Obese children and those 7 years of age and older are less likely to respond to montelukast and thus should be considered for surgical intervention if symptomatic. Further research is needed to determine the appropriate duration of therapy for children with mild OSA managed with anti-inflammatory medications and the impact of these medications on symptom burden and QOL. In the CHAT cohort,1 adenotonsillectomy resulted in significant improvements in PSG parameters, behavior, and obstructive symptomatology compared to the watchful waiting group. Seventy-nine percent of children had resolution of their OSA (AHI < 2) on postadenotonsillectomy PSG. Complications in children undergoing surgery for mild OSA were rare. Volsky et al.5 also demonstrated significant improvements in QOL when comparing children with mild OSA undergoing adenotonsillectomy to those being observed. The authors noted that validated, disease-specific QOL assessments, such as the OSA-18 survey, might be useful in determining which children with mild OSA will benefit from early adenotonsillectomy. Children with mild OSA and baseline OSA-18 QOL scores > 70 were more likely to experience an increase in their obstructive symptoms following a period of observation; thus, these children may be good candidates for early adenotonsillectomy. Multiple therapeutic options may be effective for treating mild pediatric OSA including observation, management with anti-inflammatory medications, and surgery (Table 1). Validated instruments that assess symptom burden and the impact of OSA on QOL may be useful in determining which treatment option is most appropriate for the child. Shared decision making between caregiver, child (when appropriate), and physician may be useful in developing a management strategy for mild OSA. Data on the sequelae of mild OSA in children, including the impact of obstruction on cardiovascular parameters and neurocognition, are lacking. Future research is needed to compare long-term outcomes for the different treatment options for mild OSA in children. Marucs et al.,1 Chan et al.,3 and Goldbart et al.,4 are high-quality, randomized level 1 studies. Volsky et al.5 is a level 2 prospective comparative study. Li et al.2 is a level 3 study.
No takes yet. Share an insight, caveat, or question.
Baldassari et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: